Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Gilead, CRF commence ranolazine Phase 3 clinical trial for chronic stable angina in post-PCI setting

Gilead Sciences, Inc. and the Cardiovascular Research Foundation (CRF) today announced the initiation of RIVER-PCI (Ranolazine for Incomplete VEssel Revascularization post-PCI), a Phase 3 clinical trial evaluating the utility of ranolazine to prevent major adverse cardiovascular events (MACE) in patients with a history of chronic angina who have incomplete revascularization following percutaneous coronary intervention (PCI).

7 Nov 2011

InfraReDx TVC Imaging System to be exhibited at TCT 2011

InfraReDx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced that its TVC Imaging System for the true vessel characterization of coronary artery disease will be highlighted during the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT 2011).

7 Nov 2011

InfraReDx launches enhanced version of LipiScan IVUS Coronary Imaging System

InfraReDx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced the launch of its TVC Imaging System, an enhanced version of the LipiScan IVUS Coronary Imaging System.

7 Nov 2011

Dual imaging approach could improve diagnosis, treatment of coronary artery disease

A new device that combines two microimaging technologies can reveal both the detailed anatomy of arterial linings and biological activities that, in coronary arteries, could indicate the risk of heart attacks or the formation of clots in arterial stents.

7 Nov 2011

Anti-TNFs, methotrexate may reduce risk of cardiovascular disease in people with RA

Taking methotrexate or anti-TNFs is associated with a reduction in risk of cardiovascular disease in people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Medtronic highlights scientific sessions of interest on program for TCT 2011

Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.

From Medtronic 5 Nov 2011

Role of cardiovascular magnetic resonance in clinical cardiology

Cardiovascular Magnetic Resonance (CMR) has undergone substantial development and offers important advantages compared with other well-established imaging modalities.

3 Nov 2011

FDA approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

Abbott today announced it has received U.S. Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

2 Nov 2011

New drug could combat cardiovascular disease

A new therapy being studied in non-human primates by researchers at Wake Forest Baptist Medical Center and colleagues is demonstrating promise as a potential tool for combating cardiovascular disease by increasing good cholesterol and lowering triglycerides in the blood.

29 Oct 2011

Apnex Medical's HGNS System receives CE Mark approval for treatment of OSA

Apnex Medical, Inc., has received CE Mark approval for its Hypoglossal Nerve Stimulation System for use by people who suffer from obstructive sleep apnea.

28 Oct 2011

Clinical and genetic risk factors associated with early stent thrombosis

Patients with certain genes or specific factors related to use of the anti-clotting drug clopidogrel are more likely to experience a blood clot within a coronary stent shortly after placement, according to a study in the October 26 issue of JAMA.

27 Oct 2011

Scientists discover gene variants that contribute to early stent thrombosis

In a first-of-its-kind study, researchers from Mount Sinai School of Medicine have discovered several gene variants contributing to early stent thrombosis (ST), a devastating and often deadly complication after coronary stent implantation in people with coronary artery disease.

27 Oct 2011

Study: Heart transplantation is a very safe and effective therapy

Heart transplantation is a very safe and effective therapy, according to a new long-term study presented today at the Canadian Cardiovascular Congress 2011, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

24 Oct 2011

Cardiac rehab boosts longevity, especially in patients with lowest fitness levels

Cardiac rehabilitation boosts longevity, especially in patients with the lowest fitness levels, Dr. Billie-Jean Martin today told the Canadian Cardiovascular Congress 2011, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

24 Oct 2011

Health prevention strategies can help Canadians achieve optimal health

Health prevention strategies to help Canadians achieve their optimal health potential could add a decade or more of healthy years to the average lifespan and save the economy billions of dollars as a result of reduced cardiovascular disease, says noted cardiologist Dr. Clyde Yancy.

21 Oct 2011

CJC publishes paper on safety of cardiac imaging methods

Canadian Journal of Cardiology has published a paper on the safety of cardiac imaging methods. This study is important for patients worried about radiation exposure during X-ray based studies of the heart. X-ray based methods have greatly improved the diagnosis of heart disease, but they can produce significant levels of radiation exposure.

20 Oct 2011

Sex differences in heart disease

Heart disease affects men and women in different ways. In women, symptoms of burgeoning heart disease are often more insidious, but when a heart attack strikes, it is more lethal than it is in men. Roughly 25 percent of men will die within a year of their first heart attack, but among women, 38 percent will die. Women are twice as likely as men to have a second heart attack within 6 years of their first one, and women are twice as likely as men to die after bypass surgery.

15 Oct 2011

New DCE-CT technique gives better clues to future cardiac events in heart patients

A new non-invasive technique for measuring how well the heart and blood vessels function in patients already suffering from coronary artery disease could, in a single test, identify which abnormally narrowed blood vessels are the most likely to lead to further cardiovascular complications.

11 Oct 2011

FDA clears Cardium's new Excellagen topical gel for diabetic foot ulcers

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

11 Oct 2011

Cardium's Excellagen topical gel for diabetic foot ulcers receives FDA 510(k) clearance

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen™ professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

10 Oct 2011